Science and Technology Part 7: IPR in India — Patents, GI Tags and Compulsory Licensing, Exam-Ready Notes

Category: Civil Exams · Series: Science and Technology (GS Paper 3) · Read time: ~9 minutes**

Intellectual-property questions test the statutory map (the patents-trademarks-copyright-GI-designs set), the TRIPS interface, and the two Indian flashpoints: GI tags (the current-affairs stream) and compulsory licensing (the pharma-access debate). This note covers the full IP file.

Table of Contents

1. The IP Family: The Statutory Map
2. Patents: The Law and the Standards
3. Compulsory Licensing and the Pharma Debate
4. GI Tags: The System and the Famous List
5. TRIPS and the International Layer
6. How Exams Probe This Topic
7. Quick Revision: One-Glance Facts

1. The IP Family: The Statutory Map

• The administered-by fact. DPIIT (Commerce Ministry) administers patents, trademarks, GI and designs; the Copyright Office under the Education/HRD Ministry; the PPV Authority under Agriculture — the ministries’ map MCQ.

2. Patents: The Law and the Standards

• The patentability triad.**Novelty, inventive step (non-obviousness), industrial applicability — plus full disclosure (the quid pro quo: 20-year exclusivity for teaching the world to practise it); non-patentable list (S.3-4): discoveries, mathematical methods, business methods, computer programs per se, traditional knowledge, agriculture-horticulture methods, Section 3(d)’s new-use/pharmaceutical-derivative bar** — the Novartis-clause (below).
• The international-novelty arc. India’s post-2005 regime: product patents in all technologies (the pre-2005 mailbox era and EMR — exclusive marketing rights — closed); the 2005 amendment’s TRIPS-compliance; the pre-grant and post-grant opposition provisions (India’s strong civil-society check).
• The grants picture. India’s patent filings rising (~85-90k applications; ~1 lakh+ grants 2023-24; the Japan-US-EU dominance; domestic filings’ rise — the 2024-25 record domestic share); the pendency critique and the AI-assisted-examination push.

3. Compulsory Licensing and the Pharma Debate

• The provision.**Section 84 (Patents Act): after 3 years from grant, any person can seek a compulsory licence on three grounds — reasonable-requirement-of-public not met, not available at reasonably affordable price, not worked in India; Section 92 (national emergency/extreme urgency — the pandemic trigger), Section 92A** (export to countries with no capacity — the Doha-paragraph-6 implementation).
• The case.**Natco v. Bayer (2012 — the sorafen/Nexavar licence: the first Indian CL, royalty ~6-7%, the “reasonably affordable price” reasoning) — the only full CL granted; the subsequent (Bristol-Myers’ dasatinib refusal) line; the Section 3(d) twin: Novartis v. Union of India (2013** — the SC rejecting the Glivec patent: derivatives must show enhanced efficacy — the evergreening bar).
• The debate.**Pharma-access advocates: India as the “pharmacy of the developing world” — CLs and 3(d) keep generics flowing; innovator-industry critique: investment chilling, the US Special-301 watch-list placements; the balanced line:** CLs are TRIPS-legal, rarely used, and the pandemic (COVID-era waiver debates — the TRIPS vaccine-waiver of 2022) proved the flexibilities’ worth — the mains both-flanks.

4. GI Tags: The System and the Famous List

• The system. Registered by the GI Registry (Chennai) under the 1999 Act; a GI links a product’s quality/reputation to its geography (Darjeeling tea the flagship); any association/producer-body applies; infringement actionable; ~600 registered GIs (2025 — the number rises through the year; Tamil Nadu and UP lead the counts).
• The recent stream (the current-affairs staple). The 2023-25 tags — from Kashmir saffron-type staples to the year’s additions (e.g., the Assam’s products, Kerala’s tribal-crafts entries, the UP’s textiles — track the current releases before your exam; two-three latest tags as examples suffice).
• The famous litigation.**Darjeeling tea’s protection (the first Indian GI, 2004-05); the basmati battles (India-Pakistan’s joint-claim and the EU registration contests); the turmeric-neem-basmati biopiracy cases (the TKDL’s origin-story)** — the traditional-knowledge-defense trio.
• The TKDL.**Traditional Knowledge Digital Library** — the prior-art database (Ayurveda-Unani-Siddha-Yoga; the multilingual format defeating foreign patents on turmeric-type knowledge) — the defensive-publication instrument examiners love.

5. TRIPS and the International Layer

• The frame.**TRIPS (1995, the WTO’s annex) — the minimum-IP standards: national treatment, MFN, the patent-term and CL flexibilities (Articles 27, 31, 31bis); the transition periods’ expiry; the Doha Declaration (2001)** on TRIPS-and-public-health (“TRIPS should be interpreted to protect public health”) — the developing-world charter.
• The 2022 waiver. The TRIPS COVID-vaccine patent waiver (the 2022 ministerial decision, extended to therapeutics-diagnostics debates) — the first-ever TRIPS waiver (partial, temporary) — the current hook.
• The treaties. PCT (patent-cooperation, the international filing route), Madrid (trademarks’ international registration), Hague (designs), Budapest, the WIPO treaties (the Copyright-and-Neighbouring, the WIPO Internet Treaties), the 2024 WIPO Treaty on IP-Genetic Resources-Traditional Knowledge (the disclosure-requirement treaty — the newest) — the treaty-purpose match-set.
• The disputes. The US Special-301 listings (India on the priority-watch list — the annual friction); the EU’s GIs-in-FTAs negotiation (the EFTA/India FTA’s GI chapter — the trade link).

6. How Exams Probe This Topic

• Prelims: the statute-right-term table; S.3(d) and the Novartis holding; the CL grounds (S.84); the TKDL’s purpose; the latest GI count and 2-3 recent tags; TRIPS’s year and the Doha framing; the ministries’ map.
• Mains: “India’s IPR regime balances innovation incentives with access — examine with the CL-and-3(d) record”; “GI tags protect collective heritage but implementation lags — discuss”; “TRIPS flexibilities and the pandemic: lessons for the global IP order.”
• Cross-links. The biotech-generic file (Part 4), the trade-policy debates (Economy), the CSIR-TKDL’s science interface.

7. Quick Revision: One-Glance Facts

• Map. Patents 1970/2005 (20 yrs, DPIIT); TM 1999; Copyright 1957/2012 (life+60); GI 1999 (~600 tags); Designs 2000; PPV&FR 2001.
• Patents. Novelty-inventive-application; S.3(d) (Novartis 2013); S.84 CL (Natco-Bayer 2012); pre/post-grant opposition.
• Global. TRIPS 1995; Doha 2001; the 2022 vaccine waiver; the 2024 WIPO TK treaty; PCT-Madrid-Hague.
• Indian instruments. TKDL; the GI Registry (Chennai); Darjeeling-basmati-turmeric cases.

Conclusion. The IPR file is one table (the statute-term map), two provisions (3(d) and Section 84) with their landmark cases, and the GI-TKDL current layer. Hold the Natco and Novartis pair as the access-versus-innovation story’s anchors, track the year’s GI additions, and both the prelims match-sets and the mains balancing act are covered.